U.S. dominates worldwide flu vaccine industry market
The 89-page report, titled “Global Influenza Vaccine Market Outlook 2020,” said that the U.S. accounted for 50 percent of the world’s influenza vaccine industry market in 2014.
Other issues driving the industry's success in the U.S. are increasing health care expenditures, the introduction of new vaccines, rising awareness, advancing technologies and increasing health consciousness.
Despite these advances, the industry still has challenges to face, including lengthy vaccine development processes, regulatory issues, testing and overall low awareness.
The report offers a detailed rational analysis and research of the future prospect and current status of the global influenza vaccine industry. It includes pipeline analysis, geographical segments analysis, pricing analysis, and mergers and acquisitions.
Also included is a discussion about the factors that helped with the increased use of FluMist, Afluria, Flucelvax, Fluarix and Anflu.